Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
Abstract Background Hydroxychloroquine and chloroquine have been used for hospitalized coronavirus disease 2019 patients because of their antiviral and anti-inflammatory function. However, little research has been published on the impact of the immunomodulatory effect of (hydroxy)chloroquine on humo...
Guardado en:
Autores principales: | Astrid Muyldermans, Piet Maes, Tony Wawina-Bokalanga, Tine Anthierens, Olivier Goldberg, Magali Bartiaux, Oriane Soetens, Ingrid Wybo, Sigi Van den Wijngaert, Denis Piérard |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/080113d2b6d1464dbdc08455fc51a929 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
por: Samar Tharwat, et al.
Publicado: (2022) -
Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines
por: Browning DJ, et al.
Publicado: (2018) -
Basic reinfection number and backward bifurcation
por: Baojun Song
Publicado: (2021) -
COVID-19 reinfection: the role of natural immunity, vaccines, and variants
por: Bao Y. Sciscent, et al.
Publicado: (2021) -
Case series: Reinfection of recovered SARS CoV‐2 patients for the third time
por: Sepideh Hasanzadeh, et al.
Publicado: (2021)